[1] Rosenthal N, Meininger G, Ways K, et al.Canagliflozin: a sodium glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus[J]. Annals of the New York Academy of Sciences, 2015, 1358(1): 28-43. [2] Bode B, StenlÖf K, Harris S, et al.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(3): 294-303. [3] Cefalu WT, Leiter LA, Yoon KH, et al.Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferi-ority trial[J]. The Lancet, 2013, 382(9896): 941-950. [4] Forst T, Guthrie R, Goldenberg R, et al.Efficacy and safety of canagliflozin over 52 weeks in patie with type 2 diabetes on background metformin and pioglitazone[J]. Diabetes Obesity & Metabolism, 2014, 16(5): 467-477. [5] Fulcher G, Matthews DR, Perkovic V, et al.Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes[J]. Diabetes Obesity & Metabolism, 2016, 18(1): 82-91. [6] Inagaki N, Kondo K, Yoshinari T, et al.Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12 week study[J]. Diabetes Obesity & Metabolism, 2013, 15(12): 1136-1145. [7] Ji L, Han P, Liu Y, et al.Cana gliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea[J]. Diabetes Obesity & Metabolism, 2015, 17(1): 23-31. [8] Lavalle-González FJ, Januszewicz A, Davidson J, et al.Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J]. Diabetologia, 2013, 56(12): 2582-2592. [9] Neal B, Perkovic V, Zeeuw DD, et al.Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapyin patients with type 2 diabetes[J]. Diabetes Care, 2015, 38(3): 403-411. [10] Rosenstock J, Aggarwal N, Polidori D, et al.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with Type 2 diabetes[J]. Diabetes Care, 2012, 35(6): 1232-1238. [11] Rosenstock J, Chuck L, Manuel González-Ortiz, et al.Initial combination therapy with canagliflozi plus metformin versus each component as monotherapy for drug-naive type 2 diabetes[J]. Diabetes care, 2016, 39(3): 353-362. [12] StenloF K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherap in patients with type 2 diabetes inadequately controlled with diet andexercise: findings from the 52-week CANTATA-M study[J]. Current Medical Research and Opinion, 2014, 30(2): 163-175. [13] Wilding JPH, Charpentier G, Hollander P, et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial[J]. International Journal of Clinical Practice, 2013, 67(12): 1267-1282. [14] Yale JF, Bakris G, Cariou B, et al.Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease[J]. Diabetes Obesity & Metabolism, 2013, 15(5): 463-473. [15] Yale JF, Xie J, Sherman SE, et al.Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, cont-rolled trial in patients with type 2 diabetes mellitus.[J]. Clin Ther, 2017, 39(11): 2230-2242. [16] Wei FF, Sun YY, Yang Y.Meta-analysis of adverse drug reactions of ceftriaxone sodium for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(6): 351-358. [17] Nicolle LE, Capuano G, Fung A, et al.Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose cotransporter 2 inhibitor[J]. Postgrad Med, 2014, 126(1): 7-17. [18] Watts NB, Bilezikian JP, Usiskin K, et al.Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus[J]. The Journal of Clinical Endocrinology and Metabolism, 2016, 101(1): 157-166. [19] Toulis KA, Bilezikian JP, Neil Thomas G, et al.Initiation of dapagliflozin and treatment emergent fractures[J]. Diabetes Obesity & Metabolism, 2018, 20(4): 1070-1074. [20] Sven K, Stefan K, Afshin S, et al.Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride[J]. Diabetes Care, 2018, 41(8): 1809-1816. [21] Sun YX, Meng KK, Xia YK, et al.Incidence of cardiac adverse events of cisapride:a systematic review and meta-analysis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 94-100. |